Beta Bionics, Inc. BBNX
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 15.88% | -13.99% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 15.88% | -13.99% | |||
| Cost of Revenue | 17.18% | -15.09% | |||
| Gross Profit | 15.00% | -13.23% | |||
| SG&A Expenses | 12.81% | 21.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.97% | 7.57% | |||
| Operating Income | -5.39% | -50.53% | |||
| Income Before Tax | -6.89% | -62.59% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -6.89% | -62.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.89% | -62.59% | |||
| EBIT | -5.39% | -50.53% | |||
| EBITDA | -4.99% | -51.97% | |||
| EPS Basic | -6.64% | -61.70% | |||
| Normalized Basic EPS | -6.62% | -61.76% | |||
| EPS Diluted | -6.64% | -61.70% | |||
| Normalized Diluted EPS | -6.62% | -61.76% | |||
| Average Basic Shares Outstanding | 0.25% | 0.55% | |||
| Average Diluted Shares Outstanding | 0.25% | 0.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||